Education
About Us
Working with TipRanks
Follow Us
Femasys (FEMY)
NASDAQ:FEMY
FEMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.31 - $1.80
Previous CloseN/A
Volume25.00K
Average Volume (3M)2.18M
Market Cap
$15.47M
Enterprise Value$32.53M
Total Cash (Recent Filing)$3.22M
Total Debt (Recent Filing)$7.85M
Price to Earnings (P/E)―
Beta-1.00
Next Earnings
Nov 06, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding43,009,995
10 Day Avg. Volume886,405
30 Day Avg. Volume2,178,063
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.10
Enterprise Value/Revenue17.24
Enterprise Value/Gross Profit32.10
Enterprise Value/Ebitda-1.77
Forecast
1Y Price Target
$3.83Price Target Upside994.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Leadership And ManagementThe appointment of Kelly Nicholas as Chief Commercial Officer is expected to help drive sales growth due to her extensive experience in commercializing medical devices.
Regulatory ApprovalFemaSeed obtained FDA 510(k) clearance, offering a novel and unique form of artificial insemination that could increase pregnancy success rates.
Strategic PartnershipFemasys has secured a significant strategic partnership with Kebomed to commercialize its FemBloc across France and the Benelux region, marking a major step in its European growth strategy.
Bears Say
Revenue Performance2Q25 revenues lower than estimated; though room for growth is on the horizon.
Sales PerformanceThe sales ramp is slower than anticipated, leading to a lower 2025 revenue estimate.
Femasys News
FEMY FAQ
What was Femasys’s price range in the past 12 months?
Femasys lowest stock price was $0.31 and its highest was $1.80 in the past 12 months.
What is Femasys’s market cap?
Femasys’s market cap is $15.47M.
When is Femasys’s upcoming earnings report date?
Femasys’s upcoming earnings report date is Nov 06, 2025 which is in 37 days.
How were Femasys’s earnings last quarter?
Femasys released its earnings results on Aug 08, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.003.
Is Femasys overvalued?
According to Wall Street analysts Femasys’s price is currently Undervalued.
Does Femasys pay dividends?
Femasys does not currently pay dividends.
What is Femasys’s EPS estimate?
Femasys’s EPS estimate is -0.12.
How many shares outstanding does Femasys have?
Femasys has 43,009,995 shares outstanding.
What happened to Femasys’s price movement after its last earnings report?
Femasys reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went down -12.36%.
Which hedge fund is a major shareholder of Femasys?
Currently, no hedge funds are holding shares in FEMY
Femasys Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.83 (994.29% Upside)
$3.83 (994.29% Upside)
Blogger Sentiment
Bullish
FEMY Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.23%
12-Months-Change
Fundamentals
Return on Equity
-329.45%
Trailing 12-Months
Asset Growth
-32.04%
Trailing 12-Months
Company Description
Femasys
Femasys Inc. (FEMY) is a biomedical company that operates in the healthcare sector, specifically focusing on women's health. The company is dedicated to developing innovative medical solutions for female reproductive health. Its core products include non-surgical permanent birth control and infertility treatment technologies, aimed at providing less invasive and more accessible healthcare options for women.
FEMY Stock 12 Month Forecast
Average Price Target
$3.83
▲(994.29% Upside)
Technical Analysis
Harvard Bioscience
―
Retractable Technologies
―
Milestone Scientific
―
Predictive Oncology
―
Meihua International Medical Technologies Co., Ltd.
―
Ownership Overview
4.23% Insiders
2.72% Mutual Funds
7.51% Other Institutional Investors
83.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---